

Report Title	Integrated Quality & Performance Report - July 2020		
Sponsoring Executive	Dave Baker, Director of Partnerships and Innovation		
Report Author	Yasmina Gainer, Head of Performance and Costing		
Meeting	Public Board	Date	3 September 2020

1. Suggested discussion points *[two or three issues you consider the Board should focus on]*

- On Restoration and Recovery key markers show that we have begun to get back on top of cancer with 31 day (93.6% v 91.8%) and 62 day (67% v 56%) performance improving in July. Non Cancer performance has not bottomed out yet with: backlog increasing (17000 v 14000); RTT declining (53% v 58.2%) and incomplete 52 week waits almost doubling to 178. Priorities are twofold: Assessing and meeting clinical prioritisation dates and forecasting recovery based upon production plan and the NHSE/I phase 3 letter.
- ED activity levels are now at 74% of last year. Performance has dropped to 86% (90%) in month suggesting that a return to the demand levels of last year will cause further underperformance. Sandwell Hospital is the key issue with the focus being on better flow in the day to ease pressure in the evening.
- District nurse (Community) acquired pressure ulcers rose steeply in month to 41 (29). Work is under way to establish root cause.
- Mortality rates have risen again to 122 against HSMR with high weekend mortality rate of 128 and weekday at 120 which is now showing elevated levels. The Medical Directors office is looking into comparisons with other Trusts and the cause of the divergence between weekend and weekday.
- Some good progress on persistent reds. Neutropenic Sepsis achieves 93% and was only 1 minute for one patient off achieving 100%. Stroke ward admissions and theatre cancellations achieve target. MRSA screening continues to improve. However, having succeeded in May, FNOF performance has not maintained and drops further to 53.1% (60%).

2. Alignment to 2020 Vision *[indicate with an 'X' which Plan this paper supports]*

Safety Plan	X	Public Health Plan	X	People Plan & Education Plan	X
Quality Plan	X	Research and Development		Estates Plan	
Financial Plan	X	Digital Plan		Other <i>[specify in the paper]</i>	

3. Previous consideration *[where has this paper been previously discussed?]*

OMC, WD5 Group Distribution to Group Management Boards, PMC, CLE, Q&S

4. Recommendation(s)

The Board are asked to:

- Note the performance for July 2020; Assure itself that performance of clinical indicators is in line with expectations or actions.
- Assure itself that there we will be able to monitor performance against clinical prioritisation dates forecast RTT recovery based on production plan and NHSE/I Phase 3 letter

5. Impact *[indicate with an 'X' which governance initiatives this matter relates to and where shown elaborate]*

Trust Risk Register	X	Numerous				
Board Assurance Framework	X	SBAF 11: Labour Supply and SBAF 14: Amenable Mortality				
Equality Impact Assessment	Is this required?	Y		N	X	If 'Y' date completed
Quality Impact Assessment	Is this required?	Y		N	X	If 'Y' date completed